InvestorsHub Logo
Followers 15
Posts 697
Boards Moderated 0
Alias Born 10/03/2017

Re: None

Thursday, 04/11/2024 12:11:57 AM

Thursday, April 11, 2024 12:11:57 AM

Post# of 426602
Review | Open Access | 7 Apr 2024
Lipid-lowering therapies in patients undergoing percutaneous coronary intervention

https://www.oaepublish.com/articles/2574-1209.2023.136

“Furthermore, icosapent ethyl, a purified derivative of eicosapentaenoic acid, targets hypertriglyceridemia and has shown cardiovascular benefits compared to placebo. In this article, we delve into the mechanisms of blood lipids and molecular targets in connection with CAD undergoing PCI. We also explore the current landscape of available LLT options, guidelines in practice, and the subtleties of therapy.”
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News